CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 177.27M shares rose 103.5% year over year, ahead of the +90.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 4.2% from the prior quarter. Over 3 fiscal years it compounded at +28.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +103.5% holds above the trailing-twelve-month pace of +90.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
177.27M+4.2% QoQ
Last fiscal yearDec 2025
137.94M+63.4% YoY
LTMMar 2026
160.38M+90.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103.5%——
1 year+63.4%——
3-year CAGR+28.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
137.94M USD
Year-over-year change
+63.4%
4-year CAGR
+21.1%

Weighted Avg Shares vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 weighted avg shares of 160.38M shares is the highest of the 10 companies compared; the peer median is 72.36M shares.
  • Its year-over-year change of +90.3% is the highest of 9, against a peer median of +4.0%.
  • Over three fiscal years its annual growth of +28.0% compares with a peer median of +12.4%.
CTMX Competitors Peer median
Weighted Avg Shares for CTMX and competitors
Company Period LTM YoY 3-year CAGR
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.3%+28.0%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
ZYMEZymeworks Inc.LTM Sep 202673.65M -2.5%+4.9%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
ADAGAdagene Inc.LTM Jun 202435.12M —+2.9%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding CTMX) 72.36M+4.0%+12.4%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.